Clinical Trial Update: Rapamune Improves Outcomes of Severe H1N1 Pneumonia [Phase 2]

View source ↗

Summary

A Phase 2 trial of sirolimus (Rapamune) in severe H1N1 influenza pneumonia reported improved outcomes in patients with hypoxemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonia Due to H1n1 Influenza

Drugs mentioned

• Rapamune (sirolimus)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: H1N1 Pneumonia, Hypoxemia | Phase 2 | Status: COMPLETED